Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-28T07:40:58.175Z Has data issue: false hasContentIssue false
  • English
  • Français

Vancomycin Use in a University Medical Center: Effect of a Vancomycin Continuation Form

Published online by Cambridge University Press:  02 January 2015

Martin E. Evans ,
Eric T. Millheim  and
Robert P. Rapp
Martin E. Evans*
Affiliation:
Division of Infectious Diseases, Department of Internal Medicine, University of Kentucky College of Medicine, Lexington, Kentucky
Eric T. Millheim
Affiliation:
Division of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, Kentucky
Robert P. Rapp
Affiliation:
Division of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, Kentucky
*
Infection Control, HG608, University of Kentucky Medical Center, 800 Rose St, Lexington, KY 40536-0084
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To examine the impact of a new policy to ensure appropriate use of vancomycin in a 461-bed tertiary-care hospital.

Design:

We instituted a policy that allowed physicians to prescribe vancomycin but that required them to complete a vancomycin continuation form and document that use conformed to Hospital Infection Control Practices Advisory Committee (HICPAC) guidelines if they wished to continue the drug beyond 72 hours. Vancomycin was stopped automatically at 72 hours if use was not consistent with guidelines, if an infectious diseases consultant did not approve the drug, or if the form was not completed. A pharmacist and infectious diseases specialist monitored use of vancomycin prospectively and interacted with prescribers when indicated. Educational efforts were limited to printing the HICPAC guidelines on the form and providing information about the policy in a newsletter. Patterns of prescribing and the economic impact of the form were evaluated over a 6-month period.

Results:

Only 29% to 48% of vancomycin orders initially met HICPAC guidelines, but 77% to 96% of use was appropriate after 72 hours when the form was used. Inappropriate surgical prophylaxis, empirical therapy of intensive-care unit and transplant patients, and therapy for inadequately documented coagulase-negative staphylococcal infections remained problems. Vancomycin use fell from a mean of 136 (±52) g/1,000 patient days in the 12 months before the form to 78 (±22) g/1,000 patient days in the 9 months after institution of the form (P<.05). Net vancomycin acquisition costs and costs of ordering vancomycin serum levels fell by $357 and $19 per 1,000 patient days, respectively (P<.05). This represented annualized saving of approximately $47,000 in drug and monitoring costs. No adverse patient outcomes were seen as a result of the program.

Conclusions:

A vancomycin continuation form can decrease inappropriate vancomycin use and may save money. Additional educational efforts may be required to increase compliance with HICPAC guidelines during initial prescribing.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 20 , Issue 6 , June 1999 , pp. 417 - 420
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1999

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Evans, ME, Kortas, KJ. Vancomycin use in a university medical center: comparison with hospital infection control practices advisory committee guidelines. Infect Control Hosp Epidemiol 1996;17:356–359.Google Scholar
2. Pestotnik, SL, Classen, DC, Evans, S, Burke, JP. Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Ann Intern Med 1996;124:884–890.Google Scholar
3. Frank, MO, Batteiger, BE, Sorensen, SJ, Hartstein, AI, Carr, JA, McComb, JS, et al. Decrease in expenditures and selected nosocomial infections following implementation of an antimicrobial-prescribing improvement program. Clinical Performance and Quality Health Care 1997;5:180–188.Google Scholar
4. Adachi, W, Bolding, F, Armstrong, R. Experience with vancomycin education and order sheet to limit vancomycin use. Hospital Pharmacy 1997;32:1370–1373.Google Scholar
5. Burke, CE, Piper, J, Holloway, W. Order form for restricting vancomycin prescribing. Am J Health Syst Pharm 1997;54:1893–1987.Google Scholar
6. McGowan, JE. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance? Infect Control Hosp Epidemiol 1994;15:478–483.Google Scholar
7. Hospital Infection Control Practices Advisory Committee, Centers for Disease Control and Prevention. Preventing the spread of vancomycin resistance: a report from the Hospital Infection Control Practices Advisory Committee prepared by the subcommittee on prevention and control of antimicrobial-resistant microorganisms in hospitals. Infect Control Hosp Epidemiol 1995;16:105–113.Google Scholar
8. Centers for Disease Control and Prevention. Drug-resistant Streptococcus pneumoniae—Kentucky and Tennessee, 1993. MMWR 1994;43:23–25.Google Scholar
9. Montecalvo, MA, Horowitz, HW, Nadelman, R, Nowakowski, J, Andryshak, C, Colbi, D, et al. Controlling IV vancomycin on an oncology unit by infectious diseases consultation. In: Program and Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy; September 1995; San Francisco, CA. Abstract 107.Google Scholar
10. Singer, MV, Haft, R, Barlam, T, Aronson, M, Shafer, A, Sands, KE. Vancomycin control measures at a tertiary-care hospital: impact of interventions on volume and patterns of use. Infect Control Hosp Epidemiol 1998;19:248–253.Google Scholar
11. Morgan, AS, Brennan, PJ, Fishman, NO. Impact of a vancomycin restriction policy on use and cost of vancomycin and incidence of vancomycin-resistant Enterococcus . Ann Pharmacother 1997;31:970–973.Google Scholar
12. Anglim, AM, Klym, B, Byers, KE, Scheid, WM, Farr, BM. Effect of a vancomycin restriction policy on ordering practices during an outbreak of vancomycin-resistant Enterococcus faecalis . Arch Intern Med 1997;157:1132–1136.Google Scholar
13. Belliveau, PP, Rothman, AL, Maday, CE. Limiting vancomycin use to combat vancomycin-resistant Enterococcus faecium . Am J Health Syst Pharm 1996;53:1570–1575.Google Scholar
14. Morris, JG, Shay, DK, Hebden, JN, McCarter, RJ, Perdue, BE, Jarvis, W, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med 1995;123:250–259.Google Scholar